If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Sunitinib Extends Progression-Free Survival in Patients With Neuroendocrine Tumours of the Pancreas: Presented at ASCO-GI By Ed Susman ORLANDO, Fla -- January 25, 2010 -- Treating neuroendocrine tumours of the pancreas with sunitinib more than doubles progression-free survival compared with placebo, according to a phase 3 study presented here at the 2010 Gastrointestinal Cancers Symposium (ASCO-GI). “We found a significant improvement in progression-free survival -- 11.4 months with sunitinib versus 5.5 months with placebo [P < .0001],” said Eric Raymond, MD, Medical Oncology Department, Hôpital Beaujon, Clichy, France, during a poster presentation on January 23. “We also observed a significant survival benefit, with about a 60% reduction in the risk of health [P = .0204] if a person was taking sunitinib for these cancers.” While the percentage of patients who achieved an objective response was just 9.3%, it was still significant compared with placebo patients, none of whom achieved a partial response to therapy. “What we also observed is that even though these neuroendocrine tumours of the pancreas are considered slow-growing cancers, we saw that if you don’t treat these tumours, they are no longer indolent,” said Dr. Raymond. Dr. Raymond presented final results from a randomised, international, double-blind trial in patients with advanced neuroendocrine tumours that was halted almost a year ago with only about half of the planned patients (340) enrolled at the recommendation of the Independent Safety Data Monitoring Committee due to differences in efficacy. In the trial, 86 patients with progressive, well-differentiated, malignant pancreatic neuroendocrine tumours were randomly assigned to receive sunitinib 37.5 mg/day plus best supportive care while another 85 patients were assigned to receive placebo plus best supportive care. “The magnitude of sunitinib’s benefit in the pancreatic neuroendocrine tumour patient population was an encouraging finding,” said Dr. Raymond. “These findings offer hope to a patient population for whom there are limited treatment options.” Adverse events were similar to those observed in other sunitinib studies. The most commonly reported grade 3/4 adverse events in the sunitinib arm were neutropenia (12%), hypertension (9.6%), hand-foot syndrome (6%), and leucopenia (6%). Funding for this study was provided by Pfizer. The 2010 Gastrointestinal Cancers Symposium is sponsored by the American Gastroenterological Association Institute, the American Society of Clinical Oncology, the American Society for Therapeutic Radiation Oncology, and the Society of Surgical Oncology. [Presentation title: Updated Results of the Phase III Trial of Sunitinib (SU) Versus Placebo (PBO) for Treatment of Advanced Pancreatic Neuroendocrine Tumors (NET). Abstract 127]
|
